

09-18-2008

RECEIVED
CENTRAL FAX CENTER

SEP 15 2008

Patent and Trademark Office



103525375

ed original documents or copy thereof.

Atty Ref/Docket No.: 2845.001US2

To the Director of the U.S. Patent and

1. Name of conveying party(ies):

Name: Bradley Pharmaceuticals, Inc.

Street Address: 383 Route 46 West

City: Fairfield State: New Jersey Zip: 07004

Additional name(s) of conveying party(ies) attached?

[] Yes [X] No

3. Nature of conveyance:

- [] Assignment [X] Merger
- [] Security Agreement [] Change of Name
- [] Other

Execution Date: April 03, 2008

2. Name and address of receiving party(ies):

Name: Nycomed US Inc.

Street Address: 60 Baylis Road, P.O. Box 2006

City: Melville State: NY Zip: 11747-0103

Additional name(s) & address(es) attached? [] Yes [X] No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

SEE ATTACHED SCHEDULE A

B. Patent No.(s)

SEE ATTACHED SCHEDULE A

Additional numbers attached? [] Yes [X] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Warren D. Woessner

Address:

Schwegman, Lundberg & Woessner, P.A.
P.O. Box 2938
Minneapolis, MN 55402-0938

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$1,000.00

[] Enclosed

[X] Authorized to be charged to deposit account
19-0743

8. Please charge any additional fees or credit any over payments to our Deposit Account No.: 19-0743

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Warren D. Woessner/Reg. No. 30,440

Name of Person Signing

Signature

9-15-08

Date

Total number of pages including cover sheet: 9

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Mail Stop Assignment Recordation Services
P.O. Box 1450
Alexandria, VA 22313-1450

09/17/2008 DBYRNE 00000019 190743 10737831
01 FC:8021 1000.00 DA

80-51-5

SCHEDULE A				
ATTY. DOCKET #	TITLE	STATUS	FILING/ISSUE DATE	SERIAL/PATENT NUMBER
2845.001US2	NOVEL BENZOYL PEROXIDE COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Pending	18-Dec-03	10/737,831
2845.002US1	METHOD AND COMPOSITION FOR TREATING DERMATOLOGICAL CONDITIONS	Pending	29-Oct-04	10/976,182
2845.003US2	METHOD AND APPARATUS FOR DISPENSING A COMPOSITION	Pending	05-Jan-07	11/649,794
2845.003US3	METHOD AND APPARATUS FOR DISPENSING A COMPOSITION	Pending	07-Aug-08	12/187,781
2845.004US1	NOVEL COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Issued	11-Feb-03	7,074,832
2845.005US1	DERMATOLOGICAL COMPOSITION	Issued	02-Apr-98	5,919,470
2845.006US1	NASAL IRRIGATION SYSTEM	Issued	24-Jun-98	5,899,878
2845.007US1	METHOD OF TREATING ONYCHOMYCOSIS	Issued	12-Apr-00	6,281,239
2845.007US2	METHOD OF TREATING ONYCHOMYCOSIS	Issued	29-Jun-01	6,380,236

2845.008US1	NOVEL COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Issued	24-Sep-01	6,429,231
2845.008US2	NOVEL COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Issued	10-May-02	7,067,556
2845.008USX	Reexamination of U.S. Patent No. 7,067,556-- NOVEL COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Pending	17-May-07	95/000,263
2845.008UX2	Reexamination of U.S. Patent No. 6,429,231 - COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Pending	07-Jan-08	95/000,319

2845.009US1	UREA COMPOSITIONS AND THEIR METHODS OF MANUFACTURE	Pending	20-May-04	10/849,531
2845.009US2	UREA COMPOSITIONS AND THEIR METHODS OF MANUFACTURE	Pending	16-Sep-05	11/227,102
2845.011US1	NOVEL TOPICAL PHARMACEUTICAL BASE WITH ANTI- PRURITIC AND/OR ANTI- INFLAMMATORY DRUGS	Issued	13-Dec-01	6,495,602
2845.012US1	NOVEL CARBAMIDE PEROXIDE COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Issued	23-Apr-02	6,573,301
2845.012US2	NOVEL CARBAMIDE PEROXIDE COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE	Issued	26-Feb-03	6,960,615
2845.013US1	METHOD OF TREATING ONYCHOMYCOSIS	Issued	20-Mar-02	6,673,842
2845.014US1	METHOD OF TREATING FUNGAL CONDITIONS OF THE SKIN	Issued	20-Feb-03	6,986,896
2845.015US1	METHOD OF TREATING ONYCHOMYCOSIS WITH UREA AND AN ANTIOXIDANT	Issued	22-Apr-02	6,743,417
2845.016US2	METHOD OF TREATING ACTINIC KERATOSIS	Pending	28-Jul-04	10/900,279

2845.017US1	DERMATOLOGICAL COMPOSITION CONTAINING UREA	Issued	23-Dec-02	6,827,943
2845.023US1	METHODS AND APPLICATORS FOR TREATING DERMATOLOGICAL CONDITIONS	Pending	12-Apr-05	11/202,221
2845.024US3	METHODS OF ADMINISTERING DICLOFENAC COMPOSITIONS FOR TREATING PHOTODAMAGED SKIN, ROSACEA AND/OR ACNE	Pending	16-Apr-08	12/081,488

PLAN OF MERGER
OF
BRADLEY PHARMACEUTICALS, INC.
(a Delaware corporation)
INTO
NYCOMED US INC.
(a New York corporation)

This **PLAN OF MERGER** (this "**Plan**") is entered into as of April 3, 2008 between Nycomed US Inc., a New York corporation (the "**Corporation**"), and Bradley Pharmaceuticals, Inc., a Delaware corporation (the "**Subsidiary**").

RECITALS

WHEREAS, the Corporation is the owner of all of the issued and outstanding shares of capital stock of the Subsidiary; and

WHEREAS, the Corporation has authorized the merger of the Subsidiary into the Corporation pursuant to the provisions of the Business Corporation Law of the State of New York and the General Corporation Law of the State of Delaware.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. At the Effective Time (as defined in Section 11 hereof), pursuant to the provisions of the Business Corporation Law of the State of New York and the General Corporation Law of the State of Delaware, the Subsidiary shall merge with and into the Corporation (the "**Merger**").
2. The Corporation shall be the surviving corporation of the Merger and shall continue as a corporation organized and existing pursuant to the laws of the State of New York under the name "Nycomed US Inc."
3. The Corporation was incorporated on November 16, 1998 under the name of Pharma, Inc., and its name was changed to Altana Inc. on December 30, 1998 and to Nycomed US Inc. on August 24, 2007.

4. Following the Effective Time, the corporate existence of the Corporation, with all of its purposes, powers and objects, shall continue unaffected and unimpaired by the Merger, and as the surviving corporation, it shall, from and after the Effective Time, possess all of the rights, privileges, immunities, powers and purposes of the Subsidiary, and all of the property (real, personal and intangible), causes of action and every other asset of the Subsidiary shall vest in the Corporation, and the Corporation shall assume all of the obligations and liabilities of the Subsidiary, all without further act or deed.

5. The separate corporate existence of the Subsidiary shall cease upon the effectiveness of the Merger.

6. At the Effective Time, all shares of stock of the Subsidiary which are issued and outstanding or held as treasury stock immediately prior to the Merger shall automatically, by virtue of the Merger and without any action on the part of the holder thereof, be cancelled and cease to exist without payment of any consideration with respect thereto.

7. The Certificate of Incorporation and Bylaws of the Corporation, as in effect immediately prior to the Merger, shall be those of the surviving corporation.

8. The members of the board of directors and the officers of the Corporation immediately prior to the Merger shall be the members of the board of directors and the officers, respectively, of the surviving corporation until successors are appointed in accordance with applicable law and the Certificate of Incorporation and Bylaws of the surviving corporation.

9. The Subsidiary and the Corporation will cause to be executed, acknowledged, filed and reported, the Certificate of Ownership and Merger and the Certificate of Merger, and any amendment or supplements thereof, in such form and with any such changes, additions or deletions as any officer of the Subsidiary or the Corporation shall determine to be advisable and in the best interests of the Subsidiary and the Corporation, respectively, which determination shall be conclusively evidenced by such officer's execution and delivery thereof.

10. At any time prior to the time the Certificate of Ownership and Merger filed with the Secretary of State of the State of Delaware and the Certificate of Merger filed with the Department of State of the State of New York become effective, the transactions contemplated by this Plan may be abandoned and the Certificate of Ownership and Merger and the Certificate of Merger terminated in accordance with applicable law.

11. The Merger shall be effective as of 11:59 p.m. Eastern Time on April 3, 2008 (the "Effective Time").

12. The designation and number of outstanding shares of each class of the Subsidiary, all of which are owned by the Corporation, are as follows:

<u>Designation</u>	<u>Number Outstanding</u>
Common Stock	100

13. This Plan may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement.

14. This Plan shall be governed by and construed in accordance with the internal laws of the State of New York.

[Signature page follows.]

IN WITNESS WHEREOF, this Plan has been duly approved, executed and delivered by the parties hereto as of the date first written above.

NYCOMED US INC.

By: 
Name: Arthur Dulik, Jr.
Title: Senior Vice President

BRADLEY PHARMACEUTICALS, INC.

By: 
Name: Arthur Dulik, Jr.
Title: Senior Vice President

[Signature Page to Plan of Merger]